Literature DB >> 19146750

The diagnostic utility of adenosine deaminase isoenzymes in tuberculous pleural effusions.

A E Zemlin1, L J Burgess, M E Carstens.   

Abstract

SETTING: Pleural adenosine deaminase (ADA) levels have been found to be useful in diagnosing tuberculous pleuritis. Elevated ADA levels have been attributed to ADA2 isoenzyme, although no comprehensive studies have evaluated ADA2 as a diagnostic test.
OBJECTIVE: To estimate the diagnostic accuracy of ADA and ADA2 in diagnosing tuberculous pleurisy.
METHOD: A 3-year retrospective study was carried out. ADA and ADA2 were determined on patients diagnosed according to predetermined criteria.
RESULTS: A total of 951 samples were received, including 387 patients with tuberculosis (TB). ADA values>or=52.4 U/l yielded a sensitivity, specificity and positive (PPV) and negative predictive value (NPV) respectively of 93.7% (95%CI 90.0-96.0), 88.7% (95%CI 85.7-91.3), 85.5% (95%CI 81.7-88.8) and 95.2% (95%CI 92.9-96.9). ADA2 values>or=40.6 U/l yielded a sensitivity, specificity and PPV and NPV of respectively 97.2% (95%CI 95.0-98.7), 94.2% (95%CI 91.8-96.0), 92.2% (95%CI 89.1-94.7) and 98.0% (95%CI 96.3-99.0). The chi2 and McNemar tests proved the superiority of ADA2 statistically.
CONCLUSION: ADA2 is superior to ADA in the diagnosis of tuberculous pleuritis and should be used as a routine test in the diagnostic work-up of patients with pleural effusions in areas with high TB prevalence.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19146750

Source DB:  PubMed          Journal:  Int J Tuberc Lung Dis        ISSN: 1027-3719            Impact factor:   2.373


  13 in total

Review 1.  Tuberculous pleural effusion.

Authors:  Kan Zhai; Yong Lu; Huan-Zhong Shi
Journal:  J Thorac Dis       Date:  2016-07       Impact factor: 2.895

2.  Serum adenosine deaminase and total immunoglobulin G correlate with markers of immune activation and inversely with CD4 counts in asymptomatic, treatment-naive HIV infection.

Authors:  Hayley Ipp; Annalise E Zemlin; Richard H Glashoff; Johan van Wyk; Naadira Vanker; Tim Reid; Linda-Gail Bekker
Journal:  J Clin Immunol       Date:  2012-11-16       Impact factor: 8.317

Review 3.  Advances in the diagnosis of tuberculous pleuritis.

Authors:  José M Porcel
Journal:  Ann Transl Med       Date:  2016-08

4.  Human adenosine deaminases ADA1 and ADA2 bind to different subsets of immune cells.

Authors:  Yuliia Kaljas; Chengqian Liu; Maksym Skaldin; Chengxiang Wu; Qing Zhou; Yuanan Lu; Ivona Aksentijevich; Andrey V Zavialov
Journal:  Cell Mol Life Sci       Date:  2016-09-23       Impact factor: 9.261

Review 5.  Tuberculous pleural effusion.

Authors:  José M Porcel
Journal:  Lung       Date:  2009-08-13       Impact factor: 2.584

6.  Diagnostic accuracy of adenosine deaminase and lymphocyte proportion in pleural fluid for tuberculous pleurisy in different prevalence scenarios.

Authors:  Alberto Garcia-Zamalloa; Jorge Taboada-Gomez
Journal:  PLoS One       Date:  2012-06-18       Impact factor: 3.240

7.  Exudative pleural effusion in chronic kidney disease: An aetiological dilemma.

Authors:  Gautam Ahluwalia
Journal:  Indian J Med Res       Date:  2015-03       Impact factor: 2.375

Review 8.  Pleural effusion: diagnosis, treatment, and management.

Authors:  Vinaya S Karkhanis; Jyotsna M Joshi
Journal:  Open Access Emerg Med       Date:  2012-06-22

9.  Diagnostic value of pleural fluid interferon-gamma and adenosine deaminase in patients with pleural tuberculosis in Qatar.

Authors:  Fahmi Yousef Khan; Maha Hamza; Aisha Hussein Omran; Muhannad Saleh; Mona Lingawi; Adel Alnaqdy; Mohamed Osman Abdel Rahman; Hasan Syed Ahmedullah; Alan Hamza; Ahmed Al Ani; Mehdi Errayes; Mona Almaslamani; Ahmed Ali Mahmood
Journal:  Int J Gen Med       Date:  2013-01-10

10.  Pleural fluid adenosine deaminase (pfADA) in the diagnosis of tuberculous effusions in a low incidence population.

Authors:  David T Arnold; Rahul Bhatnagar; Lynette D Fairbanks; Natalie Zahan-Evans; Amelia O Clive; Anna J Morley; Andrew R L Medford; Nicholas A Maskell
Journal:  PLoS One       Date:  2015-02-03       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.